Offering a variety of integrated visualization tools, the SiteRite 9 Ultrasound System reportedly enables the insertion of vascular access devices regardless of user experience level.
For clinicians placing central venous catheters, peripherally inserted central catheters (PICCs) and IV lines, BD has launched the SiteRite™ 9 Ultrasound System.
In addition to a 15.6-inch touch screen with enhanced image quality, the SiteRite 9 Ultrasound System enables real-time needle monitoring with the Cue™ Needle Tracking System and guided catheter tip navigation with the Sherlock 3CG+™ Tip Confirmation System, according to BD.
The company added that the system also facilitates appropriate catheter selection with a combination of automated vessel assessment tools and vessel measurement capability.
"Our latest innovation in ultrasound technology is designed to make vascular access care delivery easier and more efficient for clinicians — whether they've been on the job for years or are new to the field," said Eric Borin, the worldwide president of Medication Delivery Solutions at BD. " … We've developed a best-in-class solution to aid in insertion success on the first attempt and reduce the need for repeated needlesticks to deliver a better care experience for everyone involved."
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.